A comprehensive view of non-vaccine biologics. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Sanofi acquires Provention Bio for US$2.9B, giving Sanofi access to Provention’s approved immunotherapy Tzield designed to stall progression of type 1 diabetes; Tzield is expected to have peak sales of about US$1.2B in 2030

Pfizer to acquire biotech drug developer Seagen for US$43.0B, providing Pfizer with access to Seagen’s antibody-drug conjugate technology; Pfizer expects Seagen to generate over US$10.0B in risk-adjusted revenue by 2030

Weekly antibody treatment with dupilumab improved chronic food allergy symptoms in young adults with eosinophilic esophagitis; about 30% to 40% of patients do not respond to current treatments that include food elimination diets, proton-pump inhibitors

Convatec’s InnovaBurn placental extracellular matrix medical device gets FDA clearance for management of complex surgical wounds and burns, including partial-thickness second-degree burns; almost 500,000 people seek medical treatment for burns annually

AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate to treat gastric cancer; AstraZeneca makes US$63.0M upfront payment as part of the deal worth potential US$1.1B

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count